Bevacizumab, a recombinant humanized monoclonal antibody targeting the vascular
endothelial growth factor (VEGF), has been approved in the US as first-and second-line …

Background. Hypertension is associated with antivascular endothelial growth factor
treatment, but the clinical implications of hypertension are uncertain. To assess the …

Bevacizumab (Avastin®), a humanized therapeutic monoclonal antibody that targets
vascular endothelial growth factor, is widely used in cancer treatment. Patients who are …

Background. Hypertension is a common toxicity of bevacizumab, but the frequency of
assessment of blood pressure and standardized grading remain to be defined. This study …

Bevacizumab is a vascular endothelial growth factor-A-specific angiogenesis inhibitor
indicated as an adjunct to chemotherapy for the treatment of several types of cancer …

Background Hypertension is associated with the use of bevacizumab, an angiogenesis
inhibitor widely used in cancer therapy. Currently, the risk of severe hypertension associated …

Any of a number of therapeutic agents or chemical substances can induce transient or more
long-lasting forms of hypertension. Drugs that cause hypertension do so by either …

Background Predictive factors for efficacy of vascular endothelial growth factor pathway-
targeted therapies have not been identified or confirmed. Hypertension has been observed …

3039 Background: HTN is associated with anti-VEGF treatment (Tx), but this association has
not been well studied. To assess the prognostic and predictive importance of BV-related …

Arterial hypertension is a commonly reported side-effect in all clinical trials testing all
inhibitors of angiogenesis and especially inhibitors of vascular endothelial growth factor …